AN2 Therapeutics, Inc.
AN2 Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small-molecule therapeutics using its boron chemistry platform. Its pipeline spans hematologic and infectious diseases and oncology. Clinical-stage programs include epetraborole, being studied for polycythemia vera and Mycobacterium abscessus complex lung disease, and oral AN2-502998 for Chagas disease. Research programs include preclinical candidates targeting PI3Kα and ENPP1 in oncology, along with work in bone disorders and infectious diseases. AN2 Therapeutics grants licenses for certain compounds and products and may receive development and regulatory milestone payments, commercial milestones and royalties under licensing agreements. Its global health programs, including work on melioidosis and tuberculosis, are funded primarily through grants and other non-dilutive funding. It relies on third-party contract manufacturers for materials and drug products used in preclinical studies and clinical trials. AN2 Therapeutics is headquartered in Menlo Park, California.
No SEC Form 4 filings for $ANTX in the last 30 days.
See all $ANTX insider activity →AN2 Therapeutics (ANTX) selected AN2-504661, an oral ENPP1 inhibitor, as a development candidate for hypophosphatasia (HPP) treatment. The compound showed efficacy in preclinical studies and is expected to enter Phase 1 trials in late 2027. HPP is a rare bone disease with limited approved therapies.
AN2 Therapeutics (ANTX) received extended funding from the Gates Foundation for tuberculosis research with GSK. The collaboration focuses on boron-based inhibitors for TB treatment. AN2 expects three Phase 2 studies in 2026 and has preclinical candidates in oncology and infectious diseases.
FitzPatrick Margaret M purchased 2,098 shares of AN2 Therapeutics, Inc. (ANTX) at $5.53 on 2026-09-01.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ANTX (AN2 Therapeutics, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent ANTX coverage spans financial news, insider activity and earnings.
The announcement adds a new early‑stage asset to ANTX's pipeline, which may generate modest upside as investors anticipate future data.
Positive funding news may support the stock, but the amount is undisclosed and impact is likely modest.
Small insider purchase may signal confidence but limited material impact.
The stock’s 52-week high move is tied to improved cash runway and specific upcoming IND and enrollment milestones, despite widening losses.
Near-term catalyst is IND filing in Q3 2026 and Phase 2 enrollment starting Q4 2026, with additional Phase 2 progress in M. abscessus and Chagas.
AlphAI scores every news story that mentions ANTX with an AI model for sentiment and relevance, and aggregates insider trades from AN2 Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
AN2 Therapeutics (ANTX) selected AN2-504661, an oral ENPP1 inhibitor, as a development candidate for hypophosphatasia (HPP) treatment. The compound showed efficacy in preclinical studies and is expected to enter Phase 1 trials in late 2027. HPP is a rare bone disease with limited approved therapies.
2 min readAN2 Therapeutics (ANTX) received extended funding from the Gates Foundation for tuberculosis research with GSK. The collaboration focuses on boron-based inhibitors for TB treatment. AN2 expects three Phase 2 studies in 2026 and has preclinical candidates in oncology and infectious diseases.
1 min readFitzPatrick Margaret M purchased 2,098 shares of AN2 Therapeutics, Inc. (ANTX) at $5.53 on 2026-09-01.
1 min readAN2 Therapeutics (ANTX) reported Q2 2026 results with a wider net loss of $8.2 million, or $0.18 per share, versus $6.5 million, or $0.21 per share, in Q2 2025. R&D rose to $6.0 million from $3.2 million, while G&A fell to $2.9 million from $4.0 million. Cash was $79.9 million. The stock hit a 52-week high at $7.19.
3 min readAN2 Therapeutics, Inc. (ANTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights Expanding Phase 2 study start-up activities to support global trial of oral epetraborole in polycythemia vera Enrollment ongoing in Phase 2 investigator-initi
6 min readAN2 Therapeutics, Inc. (ANTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001880438 0001880438 2026-06-03 2026-06-03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 03,
3 min readWilliams Sarah Joanne (Principal Accounting Officer) sold 265 shares of AN2 Therapeutics, Inc. (ANTX) at $4.43 on 2026-05-29.
1 min readAN2 Therapeutics (ANTX) has established a new $80 million at-the-market (ATM) stock sale program with Jefferies to issue common stock. This move replaces a previous ATM agreement with TD Securities, under which the company had raised approximately $20 million. The company's stock currently holds a Hold rating with a $3.50 price target from analysts, while TipRanks' AI Analyst Spark rates ANTX as Neutral due to weak financial performance despite positive technicals.
2 min readAN2 Therapeutics, a clinical-stage biopharmaceutical company, announced a private placement financing expected to generate approximately $40 million in gross proceeds. The financing includes the sale of common stock and pre-funded warrants to new and existing institutional investors, including Coastlands Capital, Commodore Capital, and Vivo Capital. The proceeds will support the company's development of novel small molecule therapeutics utilizing its boron chemistry platform.
4 min readAN2 Therapeutics (ANTX) has appointed Sarah Williams as Principal Accounting Officer with an increased salary, effective February 1, 2026. Simultaneously, CFO Lucy Day's salary will be reduced as part of the company's cost-saving efforts, while her other employment terms remain largely unchanged. The company's stock currently holds a "Hold" rating with a $1.00 price target based on analyst forecasts.
3 min read
